Peptide profile · Anti-Aging
Ovagen
Hepatoprotective tripeptide bioregulator (Glu-Asp-Leu) that penetrates hepatocyte nuclei to bind DNA in the minor groove at AT-rich promoter regions, upregulates antioxidant enzymes (SOD, glutathione peroxidase, GST) beyond melatonin's capacity, and supports liver regeneration through epigenetic activation of hepatocyte proliferation and anti-fibrotic gene programs
Molecular formula
C15H25N3O8
- CAS number
- Not assigned (proprietary Khavinson peptide)
- PubChem
- 444128
- Developed · 2000s (part of Khavinson's systematic peptide bioregulator research program)
- Vladimir Khavinson, Saint Petersburg Institute of Bioregulation and Gerontology, Russia
Amino acid sequence
H-Glu-Asp-Leu-OH (EDL tripeptide — L-Glutamic acid-L-Aspartic acid-L-Leucine)10mg
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| Days 10-20 | 10 mg (1 capsule) twice daily | Twice daily with meals |
Best for supporting liver function and hepatoprotection in aging individuals & comprehensive khavinson bioregulator protocols targeting hepatic aging and metabolic health
Best for
Supporting liver function and hepatoprotection in aging individuals
Ovagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
Ovagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting hepatic aging and metabolic health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery support after hepatic injury or liver disease
Ovagen is particularly well-suited for individuals focused on recovery support after hepatic injury or liver disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for maintaining liver regenerative capacity during aging
Ovagen is particularly well-suited for individuals focused on geroprotective therapy for maintaining liver regenerative capacity during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
- Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
- Pregnancy and breastfeeding — insufficient reproductive safety data
- Severe glutamic acid metabolism disorders (extremely rare)
- Active autoimmune hepatitis in flare without physician supervision
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Ovagen use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Ovagen with similar peptides to find the best fit for your goals.
Route
Ovagen is administered Oral (capsule — standard formulation)—no injection required
Best sites
- Not applicable—this is not an injectable formulation
The Ovagen injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.
4 common side effects · 3 serious
Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies.
As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users.
Reproductive safety in animal models shows normal fetal development with no teratogenicity.
Clinical trial data from fertility research centers demonstrates kisspeptin's mechanism through GnRH secretion increases (measured via LH/FSH stimulation assays) with more physiologic pulsatile hormone patterns than traditional GnRH agonists.
Ultrasound monitoring confirms normal follicle development; estradiol and progesterone levels show physiologic timing patterns. Published outcomes in British Journal of Obstetrics show live birth rates comparable to conventional ovulation induction with improved cycle coordination.
Common side effects · experienced by some users
Mild digestive discomfort
Occasional mild digestive changes during the initial days of oral or sublingual administration, reflecting hepatobiliary function adjustments. Rare occurrence.
Management
Take with a small meal if needed. Typically mild and self-resolving within 2-3 days.
Mild fatigue
Transient fatigue during the adjustment period as hepatic gene programs recalibrate and metabolic function normalizes.
Management
Rest as needed. Usually resolves within 2-3 days. Ensure adequate hydration.
Mild headache
Occasional headache during early treatment, potentially related to hepatic metabolic adjustments.
Management
Ensure adequate hydration. Standard analgesics if needed. Self-limiting.
Minor appetite changes
Slight changes in appetite as liver metabolic function normalizes and hepatic enzyme activity adjusts.
Management
Eat regular balanced meals. Changes are typically modest and temporary.
Serious side effects
No documented serious adverse effects
No serious adverse events across any published study including the 266-person 6-8 year clinical observation, animal studies, and the 11,000-person prevention program. No hepatotoxicity, nephrotoxicity, tolerance development, or accumulation toxicity with repeated annual treatment cycles.
Management
As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ovagen
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ovagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- SafeLivagen (KEDA tetrapeptide — complementary liver bioregulator providing chromatin remodeling and enkephalinase inhibition alongside Ovagen's antioxidant and regenerative support) — May be used together under medical guidance.
- SafeEpithalon (AEDG tetrapeptide — pineal bioregulator that supports neuroendocrine function and melatonin production, complementing Ovagen's hepatoprotection) — May be used together under medical guidance.
- SafeMilk thistle (silymarin — established hepatoprotective supplement that works through different mechanisms than Ovagen's epigenetic gene regulation) — May be used together under medical guidance.
With medications
- CautionHepatotoxic medications without medical supervision — while Ovagen is hepatoprotective, monitoring is important — Use with caution—discuss with your healthcare provider.
- CautionHigh-dose alcohol — directly counteracts Ovagen's hepatoprotective mechanisms — Use with caution—discuss with your healthcare provider.
- CautionOther liver-targeted investigational compounds without medical guidance — Use with caution—discuss with your healthcare provider.
With supplements
- SafeMultivitamins — Generally safe to take alongside Ovagen. Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Limited human trials · first signs days 1-10 (during treatment course)
Evidence level
Limited human trials
60/100
Regulatory status
Research compound
Onset of effects
Gradual
(3-4 weeks)
How it works
Ovagen is an ovarian-support peptide that promotes healthy ovarian function, hormone balance, and fertility through activation of reproductive hormone pathways.
The deeper mechanism
Ovagen is a bioactive peptide complex derived from ovarian tissue containing sequences that activate growth hormone and gonadotropin signaling cascades in ovarian cells.
These mechanisms enhance follicle-stimulating hormone (FSH) and luteinizing hormone (LH) responsiveness, promote healthy estrogen and progesterone production, support oocyte maturation, and improve mitochondrial function in reproductive tissues—collectively supporting fertility and reproductive health.
What to expect
Days 1-10 (during treatment course)
What you might notice
- Minimal perceptible changes — epigenetic hepatoprotective mechanisms work at the molecular level
- Possible mild digestive adjustments as hepatobiliary function recalibrates
- The EDL peptide is binding DNA promoter regions and activating antioxidant enzyme gene expression
- SOD, glutathione peroxidase, and GST upregulation is occurring at the cellular level
What's normal
- Ovagen works through gene expression regulation — effects take time to manifest
- Antioxidant enzyme levels build gradually as gene transcription increases
- Hepatocyte proliferative capacity is being enhanced but not yet measurable
- Subtle effects are normal — liver function improvements develop over weeks
What's next
- Complete the full 10-day treatment course for maximum hepatoprotective effect
- Epigenetic modifications to liver gene expression persist beyond active treatment
- Liver function improvements continue developing for weeks after the course ends
Week 2-6 (during and after treatment)
What you might notice
- Improved energy levels reflecting enhanced hepatic metabolic function
- Better tolerance to dietary and environmental challenges
- Improved liver function parameters if monitored (ALT, AST, GGT)
- Enhanced recovery capacity after physical or metabolic stress
What's normal
- Antioxidant enzyme levels are significantly elevated, providing enhanced hepatoprotection
- Hepatocyte regenerative capacity is improved
- Liver immune microenvironment is normalizing
- These molecular improvements translate gradually into functional hepatic benefits
What's next
- Benefits continue developing for weeks after the treatment course ends
- Plan the next course in 3-6 months (typically 3-4 courses per year)
- Consider combining with Livagen in subsequent courses for comprehensive liver bioregulation
Month 2-6 (inter-course period)
What you might notice
- Sustained improvements in liver function and overall vitality
- Continued hepatoprotective benefits from persistent epigenetic modifications
- Gradual return toward baseline as epigenetic effects slowly revert
- Benefits may diminish over months, indicating readiness for the next course
What's normal
- Khavinson protocols are designed as cyclical treatments (3-4 courses per year)
- Each subsequent course reinforces hepatoprotective gene activation from previous treatments
- The clinical study showed cumulative benefits over years of periodic treatment
- Long-term liver health is best supported by consistent cyclical protocols
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Ovagen over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
How does Ovagen differ from conventional liver supplements like milk thistle?
While milk thistle (silymarin) works primarily as a direct antioxidant and membrane stabilizer, Ovagen operates at a fundamentally different level — it enters hepatocyte nuclei and binds to DNA promoter sequences to activate gene expression of the liver's own endogenous antioxidant and regenerative systems. This means Ovagen upregulates the liver's capacity to produce its own SOD, glutathione peroxidase, and GST enzymes rather than simply providing external antioxidant molecules. Studies show this gene-level approach exceeds the protective effects of standard antioxidants including melatonin. The two approaches are complementary and can be used together.
What makes Ovagen a geroprotective peptide rather than just a hepatoprotective one?
Ovagen demonstrates a key characteristic of geroprotective agents: significantly greater effects in aged organisms compared to young ones. In animal studies and cell cultures, Ovagen's hepatoprotective effects were more pronounced in aged liver tissue, indicating that it specifically counteracts age-related hepatic decline rather than simply boosting already-healthy liver function. This age-preferential activity, combined with its epigenetic mechanism (DNA binding and gene regulation rather than receptor pharmacology), defines it as a genuine geroprotective hepatoprotective.
Can Ovagen help with existing liver conditions?
Preclinical studies have demonstrated Ovagen's efficacy in experimental hepatitis, liver fibrosis, and cirrhosis models — normalizing liver function, reducing hepatocyte apoptosis, and preventing fibrosis progression. However, these are primarily animal studies, and Ovagen is not approved for treating any specific liver disease in Western countries. Anyone with an existing liver condition should work with their physician and not use Ovagen as a substitute for established medical treatments.
How does Ovagen enhance antioxidant defense beyond melatonin?
Research by Kozina et al. (2007) specifically compared peptide bioregulators with melatonin for antioxidant protection. While melatonin provides direct free radical scavenging, Ovagen (EDL) upregulates gene expression of SOD (superoxide dismutase, which converts superoxide to hydrogen peroxide), glutathione peroxidase (which reduces hydrogen peroxide using glutathione), glutathione-S-transferase (which conjugates glutathione to toxins), and ceruloplasmin (which controls iron-mediated oxidative stress). By activating the genes that produce these enzymes, Ovagen creates a sustained, self-renewing antioxidant defense superior to the transient scavenging of direct antioxidants.
What is the difference between Ovagen (EDL) and Livagen (KEDA)?
Both are Khavinson hepatoprotective peptides but with different primary mechanisms. Livagen (KEDA tetrapeptide) specializes in chromatin decondensation — physically reopening silenced gene regions in aging cells — and potently inhibits enkephalinase enzymes. Ovagen (EDL tripeptide) focuses on upregulating hepatic antioxidant defenses and stimulating hepatocyte regeneration. They target different DNA promoter sequences and activate complementary sets of hepatoprotective genes, making them synergistic when used together in comprehensive liver bioregulation protocols.
Was Ovagen part of the large-scale prevention program?
Yes, liver peptide bioregulators including Ovagen were part of a comprehensive prevention program for over 11,000 industrial workers aged 35-60 years conducted by the Khavinson research group. The program used six oral peptide bioregulators targeting immune, brain, blood vessel, bronchial, liver, and cartilage tissues. Results showed comprehensive health improvements across multiple organ systems, supporting the concept of multi-organ peptide bioregulation for disease prevention.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Ovagen, on one page.
Ovagen dosing protocol